Effects of Exogenous Glucagon-Like Peptide-1 on the Blood Pressure, Heart Rate, Mesenteric Blood Flow, and Glycemic Responses to Intraduodenal Glucose in Healthy Older Subjects
Why the study?
Does intravenous GLP-1 modulate the blood pressure, heart rate, and splanchnic blood flow responses to intraduodenal glucose in healthy older subjects?
Population
10 healthy older community-dwelling subjects (9 male, 1 female; age 73.2 ± 1.5 years).
Comparison
Intravenous infusion of GLP-1 for 90 minutes… vs Intravenous infusion of saline for 90 minutes…
Design
RCT, randomized, double-blind
Follow-up
90 minutes
Authors
Discussion
Loading...
Member takes
Overview
May blunt postprandial hypotension in older adults; extends GLP-1 hemodynamic actions to splanchnic flow.
Key Points
- To determine whether exogenous GLP-1 alters blood pressure, heart rate, and splanchnic blood flow responses during intraduodenal glucose infusion in healthy older individuals.
- Conducted a double-blind randomized trial involving 10 healthy older subjects (9 male, 1 female; mean age 73.2 ± 1.5 years) in a clinical research laboratory.
- Administered an intravenous infusion of GLP-1 (0.9 pmol/kg/min) or saline (0.9%) across 90 minutes (t = -30 to 60 minutes) alongside intraduodenal glucose at 3 kcal/min (t = 0 to 60 minutes).
- During fasting (t = -30 to 0 minutes), GLP-1 produced no significant change in blood pressure or heart rate compared to saline.
- Intraduodenal glucose significantly lowered systolic blood pressure (P < .001); GLP-1 infusion attenuated this maximum systolic drop (P < .05) and showed a trend toward increasing heart rate (P = .09).
- GLP-1 significantly increased superior mesenteric artery blood flow (P < .01) and suppressed the glycemic response to intraduodenal glucose (P < .05).
Structured PICO
Does intravenous GLP-1 modulate the blood pressure, heart rate, and splanchnic blood flow responses to intraduodenal glucose in healthy older subjects?
P
Population
10 healthy older community-dwelling subjects (9 male, 1 female; age 73.2 ± 1.5 years).
I
Intervention
Intravenous infusion of GLP-1 (0.9 pmol/kg/min) for 90 minutes (t = -30 to 60 min), with intraduodenal glucose infused at 3 kcal/min between t = 0-60 min.
C
Comparator
Intravenous infusion of saline (0.9%) for 90 minutes (t = -30 to 60 min), with intraduodenal glucose infused at 3 kcal/min between t = 0-60 min.
O
Outcome
Blood pressure, heart rate, superior mesenteric artery (SMA) flow, blood glucose, and serum insulin.surrogate
Acute administration of GLP-1 attenuates the hypotensive response to enteral glucose and increases mesenteric blood flow in healthy older adults.
Cite This Study
Trahair et al. (2014) studied this question.